Skip to main content

Breast Cancer

Breast Cancer

5 mg Tamoxifen as Effective as 20 mg Daily in Early Localized Breast Cancer

Breast Cancer

Less Is More: Six Months of Traxtuzumab Equivalent to 12 Months in HER2-Positive Breast Cancer

Breast Cancer

First-in-Class Antibody-Drug Conjugate Effective in HER2-Negative Metastatic Breast Cancer

FDA Updates, Breast Cancer

Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer

Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates, Breast Cancer

Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Loretta Fala, Medical Writer

Breast Cancer

Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer

Breast Cancer

Immunotherapy Continues to Gain Momentum in Breast Cancer

Breast Cancer

Arm Morbidity Higher with Extensive Lymph Node Surgery in Younger Patients with Breast Cancer

Breast Cancer

Dose-Intense Chemotherapy Shown to Improve Outcomes in Patients with Breast Cancer

Breast Cancer

Review of Ribociclib for Advanced Hormone Receptor–Positive Breast Cancer

Lowell L. Hart, MD

8
9
10
11
12

Page 11 of 12
Results 101 - 110 of 114